June 2025's Promising Penny Stocks With Growth Potential
The United States market has been flat over the last week, but over the past 12 months, it has risen by 10.0%, with earnings forecasted to grow by 15% annually. For investors looking beyond well-known stocks, penny stocks—often representing smaller or newer companies—can present intriguing opportunities. Though the term 'penny stock' might seem outdated, these investments can still offer significant potential when backed by strong financial health and balance sheet resilience.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Imperial Petroleum (IMPP) | $3.42 | $117.7M | ✅ 4 ⚠️ 1 View Analysis > |
| New Horizon Aircraft (HOVR) | $2.22 | $69.68M | ✅ 4 ⚠️ 5 View Analysis > |
| Waterdrop (WDH) | $1.39 | $502.71M | ✅ 4 ⚠️ 0 View Analysis > |
| Greenland Technologies Holding (GTEC) | $2.09 | $36.35M | ✅ 2 ⚠️ 5 View Analysis > |
| WM Technology (MAPS) | $1.02 | $171.54M | ✅ 4 ⚠️ 1 View Analysis > |
| Tuniu (TOUR) | $0.9326 | $94.11M | ✅ 3 ⚠️ 2 View Analysis > |
| Flexible Solutions International (FSI) | $4.46 | $56.41M | ✅ 1 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.839 | $6.09M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.66 | $82.04M | ✅ 3 ⚠️ 2 View Analysis > |
| TETRA Technologies (TTI) | $3.67 | $488.38M | ✅ 4 ⚠️ 3 View Analysis > |
Click here to see the full list of 722 stocks from our US Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Nephros (NEPH)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Nephros, Inc. is a commercial-stage company that develops and sells water solutions for the medical and commercial markets in the United States, with a market cap of $53 million.
Operations: The company generates revenue primarily from its Water Filtration segment, excluding Pathogen Detection, amounting to $15.52 million.
Market Cap: $53M
Nephros, Inc., with a market cap of US$53 million, has recently shown profitability, reporting a net income of US$0.558 million for Q1 2025 compared to a loss the previous year. The company is debt-free and its short-term assets significantly exceed liabilities, indicating solid financial health. However, its earnings are forecasted to decline substantially over the next three years despite revenue growth expectations of 8.96% annually. Recent board changes include the appointment of Lisa Nettis as director for a three-year term. Nephros trades at 37.4% below estimated fair value but faces high share price volatility.
- Jump into the full analysis health report here for a deeper understanding of Nephros.
- Understand Nephros' earnings outlook by examining our growth report.
Marchex (MCHX)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Marchex, Inc. is a conversation intelligence company that offers conversational analytics and related solutions across the United States, Canada, and internationally, with a market cap of $92.52 million.
Operations: The company's revenue is primarily derived from its Conversational Analytics and Related Solutions segment, totaling $47.95 million.
Market Cap: $92.52M
Marchex, Inc., with a market cap of US$92.52 million, remains unprofitable but has reduced losses over the past five years by 44.3% annually. The company is debt-free and its short-term assets of US$19.9 million comfortably cover liabilities, providing a stable financial position despite a net loss of US$1.98 million in Q1 2025. Recent strategic expansions include partnerships with Microsoft Azure Marketplace and FordDirect, enhancing its AI-driven solutions for marketers and auto dealers to optimize customer interactions and revenue opportunities. A share repurchase program aims to buy back up to 3 million Class B common shares without an expiration date.
- Click here and access our complete financial health analysis report to understand the dynamics of Marchex.
- Examine Marchex's past performance report to understand how it has performed in prior years.
SOPHiA GENETICS (SOPH)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: SOPHiA GENETICS SA is a cloud-native software technology company focused on the healthcare sector, with a market cap of $203.14 million.
Operations: The company generates revenue from its healthcare software segment, totaling $67.17 million.
Market Cap: $203.14M
SOPHiA GENETICS, with a market cap of US$203.14 million, focuses on healthcare software and reported Q1 2025 revenues of US$17.78 million, showing growth yet remaining unprofitable with a net loss of US$17.39 million. The company has a stable financial footing, possessing more cash than its total debt and short-term assets exceeding liabilities. A strategic partnership with Precision for Medicine enhances its biomarker discovery capabilities in precision medicine, potentially accelerating drug development processes for biopharma clients. Despite increased losses over five years and no forecasted profitability soon, revenue is expected to grow annually by 20.27%.
- Click to explore a detailed breakdown of our findings in SOPHiA GENETICS' financial health report.
- Gain insights into SOPHiA GENETICS' future direction by reviewing our growth report.
Summing It All Up
- Take a closer look at our US Penny Stocks list of 722 companies by clicking here.
- Contemplating Other Strategies? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com